

A novel approach to post-acute myocardial infarction care

Avital Porter, Alon Eisen, Mark Kheifets

Department of Cardiology, Rabin Medical Center, Petach Tikva; affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Related article

by Kułach et al.

Correspondence to:

Avital Porter, MD,
Department of Cardiology,
Rabin Medical Center,
39 Ze'ev Jabotinsky St,
Petach Tikva 4941492, Israel,
phone: +972 3 9377107,
e-mail: portert@013.net;
avitalp@clalit.org.il

Copyright by the Author(s), 2023

DOI: 10.33963/KPa2023.0031

Received:

January 4, 2023

Accepted:

January 4, 2023

Early publication date:

January 28, 2023

Despite the development and implementation of novel pharmacological and technological treatments, combined with policy initiatives to deliver reductions in cardiovascular mortality, cardiovascular disease (CVD), and specifically ischemic heart disease (IHD), remains the leading cause of death worldwide. Among all CVD manifestations, acute myocardial infarction (AMI) is considered the most lethal one [1]. Short-term AMI prognosis is determined by clinical presentation, comorbidities, timing of invasive strategy, vascular access, left ventricular ejection fraction, length of hospital stay, and in-hospital complications. After discharge, cardiac rehabilitation (CR), utilization of implantable cardioverter defibrillators (ICDs) or cardiac resynchronization therapy (CRT) in eligible post-MI patients, coupled with adequate lifestyle interventions and optimal guidelines-directed medical therapy (GDMT) have all been shown to improve prognosis [2–6]. Nevertheless, despite clear recommendations by worldwide practice guidelines, large variations in their implementation among patients with AMI can still be observed [7, 8]. Limited access to cardiac outpatient care, with an emphasis on CR [9, 10], is considered a major barrier to long-term prognosis improvement [11, 12]. Thus, adherence to optimal post-AMI care is of utmost importance.

Managed Care in Acute Myocardial Infarction (MC-AMI) is a program introduced in Poland to improve the long-term prognosis of AMI patients through comprehensive, scheduled, and supervised care. The program has four core modules: I — hospitalization and acute intervention according to the European Society of Cardiology (ESC) guidelines,

II — cardiac rehabilitation, III — complete revascularization when indicated, coupled with implantation of an ICD or cardiac resynchronization therapy-defibrillator (CRT-D) in eligible patients, and IV — 12 months of scheduled outpatient cardiology care. Wita et al. [13] have previously demonstrated the importance of MC-AMI in a 12-month follow-up. Notably, differences were seen as soon as 3 months following intervention. In this current publication, Kułach et al. [14] compared the 24-month mortality rates and incidence of major adverse cardiovascular events (MACE: a composite of death, recurrent MI, and hospitalization for heart failure) in a cohort of AMI patients treated in the MC-AMI era (intention-to-treat analysis) vs. similar population treated before the MC-AMI era. The investigators analyzed 2323 consecutive patients with AMI: 1261 patients enrolled in the MC-AMI era (study group) and 1062 patients treated 12 months before the MC-AMI era (control). In the study group, 57% of patients participated in MC-AMI, while 43% remained under standard care. The treatment of MI in the MC-AMI era was associated with a 30% reduction in all-cause mortality, and a 14% reduction in MACE, although it was not related to the reduction of hospitalization for heart failure or MI in 24-month follow-up. The number needed to treat to avoid one MACE was 11 patients, and the number needed to treat to avoid one death was 19. The highest 24-month survival rate was observed in the MC-AMI enrolled patients while the patients treated in the MC-AMI era, but not enrolled, had a similar prognosis to those treated before MC-AMI was available. Multivariable Cox regression analysis within the entire cohort

showed the MC-AMI era to be inversely associated with mortality in 24-month follow-up (hazard ratio [HR], 0.5; 95% confidence interval [CI], 0.38–0.66; $P < 0.001$).

In the current study, as opposed to an earlier publication [13], intention-to-treat analysis was used, confirming an unbiased effect of the MC-AMI program. It is well known that patients who adhere to an assigned treatment do much better than those who do not adhere [15], which explains the worse outcomes in patients who did not consent or were not eligible for the program in the MC-AMI era. The present results confirm the importance of post-AMI optimal care (as implemented by the MC-AMI program) and its impact on long-term prognosis. Importantly, there were fewer women with AMI enrolled in the MC-AMI program according to the intention-to-treat analysis. Given that CR is underused in women worldwide, it is crucial to remove all barriers to post-AMI optimal care for women.

The investigators hypothesize that reduced mortality and MACE in the study group are related to components of the MC-AMI program: cardiac rehabilitation, complete revascularization, and scheduled outpatient care. Despite this being a reasonable assumption, the data to support it are lacking and deserve further evaluation. Furthermore, it is unclear whether reduced all-cause mortality is in part due to lower rates of cardiovascular mortality. Finally, the use of contemporary medications (sodium-glucose cotransporter-2 inhibitors, angiotensin receptor-neprilysin inhibitors, etc.) and different treatment goals in the MC-AMI era, in particular, that of low-density lipoprotein cholesterol, might have affected the outcomes.

It is also worth mentioning that in this study [14] AMI was not diagnosed using the latest universal definition of MI. In addition, the dataset is missing some variables, including socioeconomic and behavioral risk factors, which could potentially affect both enrollment and compliance. Last, the study was performed in a single center.

This novel study and current analysis highlight the importance of post-AMI care in the current era of evidence-based medicine, including complete revascularization, implantation of an ICD or CRT-D in eligible patients, and optimal GDMT. In conclusion, the MC-AMI program improves short and 2-year outcomes of post-AMI patients and thus can be recommended as a post-AMI program.

Article information

Conflict of interest: None declared.

Funding: None.

Open access: This article is available in open access under Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, which allows downloading and sharing articles with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at kardiologiapolska@ptkardio.pl.

REFERENCES

1. Timmis A, Vardas P, Townsend N, et al. European Society of Cardiology: cardiovascular disease statistics 2021. *Eur Heart J.* 2022; 43(8): 716–799, doi: [10.1093/eurheartj/ehab892](https://doi.org/10.1093/eurheartj/ehab892), indexed in Pubmed: [35016208](https://pubmed.ncbi.nlm.nih.gov/35016208/).
2. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Russian Journal of Cardiology.* 2021; 26(3): 4418, doi: [10.15829/1560-4071-2021-4418](https://doi.org/10.15829/1560-4071-2021-4418).
3. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J.* 2018; 39(2): 119–177, doi: [10.1093/eurheartj/ehx393](https://doi.org/10.1093/eurheartj/ehx393), indexed in Pubmed: [28886621](https://pubmed.ncbi.nlm.nih.gov/28886621/).
4. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA). *Rev Esp Cardiol (Engl Ed).* 2022; 75(5): 430, doi: [10.1016/j.rec.2022.04.004](https://doi.org/10.1016/j.rec.2022.04.004), indexed in Pubmed: [35525571](https://pubmed.ncbi.nlm.nih.gov/35525571/).
5. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2021; 42(36): 3599–3726, doi: [10.1093/eurheartj/ehab368](https://doi.org/10.1093/eurheartj/ehab368), indexed in Pubmed: [34447992](https://pubmed.ncbi.nlm.nih.gov/34447992/).
6. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of the task force of the 2018 ESC/EACTS guidelines on myocardial revascularization. *Eur Heart J.* 2019; 40(2): 204–212, doi: [10.1093/eurheartj/ehy532](https://doi.org/10.1093/eurheartj/ehy532), indexed in Pubmed: [30165435](https://pubmed.ncbi.nlm.nih.gov/30165435/).
7. Rosselló X, Huo Y, Pocock S, et al. Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality. *Int J Cardiol.* 2017; 245: 27–34, doi: [10.1016/j.ijcard.2017.07.039](https://doi.org/10.1016/j.ijcard.2017.07.039), indexed in Pubmed: [28750924](https://pubmed.ncbi.nlm.nih.gov/28750924/).
8. Alabas OA, Jernberg T, Pujades-Rodriguez M, et al. Statistics on mortality following acute myocardial infarction in 842897 Europeans. *Cardiovasc Res.* 2020; 116(1): 149–157, doi: [10.1093/cvr/cvz197](https://doi.org/10.1093/cvr/cvz197), indexed in Pubmed: [31350550](https://pubmed.ncbi.nlm.nih.gov/31350550/).
9. Kim SH, Ro JS, Kim Y, et al. Underutilization of Hospital-based Cardiac Rehabilitation after Acute Myocardial Infarction in Korea. *J Korean Med Sci.* 2020; 35(30): e262, doi: [10.3346/jkms.2020.35.e262](https://doi.org/10.3346/jkms.2020.35.e262), indexed in Pubmed: [32743992](https://pubmed.ncbi.nlm.nih.gov/32743992/).
10. Hermann M, Witassek F, Erne P, et al. Referral for cardiac rehabilitation after acute myocardial infarction: Insights from nationwide AMIS Plus registry 2005–2017. *Int J Cardiol.* 2018; 261: 1–5, doi: [10.1016/j.ijcard.2018.01.096](https://doi.org/10.1016/j.ijcard.2018.01.096), indexed in Pubmed: [29657032](https://pubmed.ncbi.nlm.nih.gov/29657032/).
11. Taylor RS, Dalal HM, McDonagh STJ. The role of cardiac rehabilitation in improving cardiovascular outcomes. *Nat Rev Cardiol.* 2022; 19(3): 180–194, doi: [10.1038/s41569-021-00611-7](https://doi.org/10.1038/s41569-021-00611-7), indexed in Pubmed: [34531576](https://pubmed.ncbi.nlm.nih.gov/34531576/).
12. Hurdus B, Munyombwe T, Dondo TB, et al. Association of cardiac rehabilitation and health-related quality of life following acute myocardial infarction. *Heart.* 2020; 106(22): 1726–1731, doi: [10.1136/heartjnl-2020-316920](https://doi.org/10.1136/heartjnl-2020-316920), indexed in Pubmed: [32826289](https://pubmed.ncbi.nlm.nih.gov/32826289/).
13. Wita K, Kulach A, Sikora J, et al. Managed Care after Acute Myocardial Infarction (MC-AMI) Reduces Total Mortality in 12-Month Follow-Up-Results from a Poland's National Health Fund Program of Comprehensive Post-MI Care-A Population-Wide Analysis. *J Clin Med.* 2020; 9(10), doi: [10.3390/jcm9103178](https://doi.org/10.3390/jcm9103178), indexed in Pubmed: [33008030](https://pubmed.ncbi.nlm.nih.gov/33008030/).
14. Kulach A, Wilkosz K, Wybraniec M. Managed Care after Acute Myocardial Infarction (MC-AMI) — Poland's nationwide program of comprehensive post-MI care — improves prognosis in 2-year follow-up. A single high-volume center intention to treat analysis. *Kardiologia Pol.* 2023; 81(2): 123–131, doi: [10.33963/KP.a2022.0260](https://doi.org/10.33963/KP.a2022.0260), indexed in Pubmed: [36404731](https://pubmed.ncbi.nlm.nih.gov/36404731/).
15. McCoy CE. Understanding the Intention-to-treat Principle in Randomized Controlled Trials. *West J Emerg Med.* 2017; 18(6): 1075–1078, doi: [10.5811/westjem.2017.8.35985](https://doi.org/10.5811/westjem.2017.8.35985), indexed in Pubmed: [29085540](https://pubmed.ncbi.nlm.nih.gov/29085540/).